Cardiovascular outcomes trials with DPP-4 inhibitors

This module summarises reported DPP-4 inhibitor CVOTs for saxagliptin (SAVOR-TIMI 53), alogliptin (EXAMINE), sitagliptin (TECOS) and linagliptin (CARMELINA®).

Cardiovascular outcomes trials with DPP-4 inhibitors
Rate this content
  • Cardiovascular outcomes trials with DPP-4 inhibitors
  • DPP-4 inhibitors are an established, non-insulin-based glucose-lowering therapy
  • CVOTs are being conducted for most compounds within the newer classes of glucose-lowering agents
  • Mechanism of action of DPP-4 inhibitors
  • Summary of completed DPP-4 inhibitor CVOTs (1/2)
Add to a new presentation
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go
Add to an existing presentation
Cancel